Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 58 of 507 for:    ASPIRIN AND P2

Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02030548
Recruitment Status : Terminated (enrolment behind expectation)
First Posted : January 8, 2014
Last Update Posted : June 6, 2019
Sponsor:
Information provided by (Responsible Party):
Medical University of Graz

Brief Summary:
The aim of the study is to evaluate surgery-related bleeding and mortality in patients needing acute coronary artery bypass grafting with or without valve replacement during dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker (Clopidogrel, Prasugrel, Ticagrelor)

Condition or disease
Acute Coronary Syndrome

Layout table for study information
Study Type : Observational
Actual Enrollment : 144 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor
Study Start Date : November 2013
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine


Group/Cohort
acute CABG
patients undergoing acute CABG with or without valve replacement during dual antiplatelet therapy



Primary Outcome Measures :
  1. calculated blood loss [ Time Frame: until postoperative day 5 ]

Secondary Outcome Measures :
  1. mortality [ Time Frame: from index surgery until one year after index surgery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
consecutive patients undergoing acute CABG with or without valve during dual antiplatelet therapy
Criteria

Inclusion Criteria:

consecutive patients undergoing acute CABG with or without valve replacement within 7 days after last intake of dual antiplatelet therapy

Exclusion Criteria:

concomitant oral anticoagulants dialysis surgery employing hypothermic cardiac arrest


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02030548


Locations
Layout table for location information
Austria
Dept. of Anesthesiology and Intensive Care Medicine
Graz, Styria, Austria, 8036
Sponsors and Collaborators
Medical University of Graz
Investigators
Layout table for investigator information
Principal Investigator: Elisabeth Mahla, MD Dept. of Anesthesiology and Intensive Care Medicine, MUG

Layout table for additonal information
Responsible Party: Medical University of Graz
ClinicalTrials.gov Identifier: NCT02030548     History of Changes
Other Study ID Numbers: NIS003684
First Posted: January 8, 2014    Key Record Dates
Last Update Posted: June 6, 2019
Last Verified: June 2019
Keywords provided by Medical University of Graz:
CABG
dual antiplatelet therapy
aspirin
clopidogrel
prasugrel
ticagrelor
Additional relevant MeSH terms:
Layout table for MeSH terms
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Ticagrelor
Prasugrel Hydrochloride
Platelet Aggregation Inhibitors
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs